Mission
Our mission is to make a sustainable impact to global women’s health with a modern, antibiotic-free treatment for common vaginal infections that women can trust for long-term effect, available when they need it.
About us
Gedea Biotech is a spin out from Lund University and was founded in 2016 by three chemists and a gynaecologist. By a modern and scientific approach, the company’s founders have made a smart innovation without antimicrobial properties that is gentle for the user and provides both quick relief and long-term cure. Gedea has run an ambitious clinical program in bacterial vaginosis and next step is CE-marking for treatment and prevention of bacterial vaginosis.
The company is privately owned and located in Lund, Sweden. Since its foundation, Gedea has received several prestigious grants and awards, among them Horizon 2020 Grant and Hoizon EIC 2023 Accelerator.
“Our ambitious clinical program has demonstrated both the efficacy and safety of our product, allowing women to trust the treatment.”
Annette Säfholm, CEO
Business model and strategy
Gedea aims to develop pHyph to a CE-marked treatment for bacterial vaginosis, estimated to reach EU approval in 2025 and to then be ready for initiating phase 3 trials for US approval as a prescription drug. Gedea aims to close partnerships with larger pharma companies for sales and marketing as well as development for regulatory approvals worldwide of the product.
